ID   SMCA2_HUMAN             Reviewed;        1590 AA.
AC   P51531; B1ALG3; B1ALG4; D3DRH4; D3DRH5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   04-NOV-2008, sequence version 2.
DT   07-APR-2021, entry version 218.
DE   RecName: Full=Probable global transcription activator SNF2L2;
DE            EC=3.6.4.-;
DE   AltName: Full=ATP-dependent helicase SMARCA2;
DE   AltName: Full=BRG1-associated factor 190B;
DE            Short=BAF190B;
DE   AltName: Full=Protein brahma homolog;
DE            Short=hBRM;
DE   AltName: Full=SNF2-alpha;
DE   AltName: Full=SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 2 {ECO:0000312|HGNC:HGNC:11098};
GN   Name=SMARCA2 {ECO:0000312|HGNC:HGNC:11098};
GN   Synonyms=BAF190B, BRM, SNF2A, SNF2L2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Liver;
RX   PubMed=8223438; DOI=10.1002/j.1460-2075.1993.tb06112.x;
RA   Muchardt C., Yaniv M.;
RT   "A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm
RT   genes potentiates transcriptional activation by the glucocorticoid
RT   receptor.";
RL   EMBO J. 12:4279-4290(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Brain;
RX   PubMed=8208605; DOI=10.1093/nar/22.10.1815;
RA   Chiba H., Muramatsu M., Nomoto A., Kato H.;
RT   "Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila
RT   brahma are transcriptional coactivators cooperating with the estrogen
RT   receptor and the retinoic acid receptor.";
RL   Nucleic Acids Res. 22:1815-1820(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH TOPBP1.
RX   PubMed=15075294; DOI=10.1101/gad.1180204;
RA   Liu K., Luo Y., Lin F.-T., Lin W.-C.;
RT   "TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-
RT   independent and E2F1-specific control for cell survival.";
RL   Genes Dev. 18:673-686(2004).
RN   [6]
RP   INTERACTION WITH CEBPA.
RX   PubMed=15107404; DOI=10.1101/gad.1183304;
RA   Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A.;
RT   "Liver tumors escape negative control of proliferation via PI3K/Akt-
RT   mediated block of C/EBP alpha growth inhibitory activity.";
RL   Genes Dev. 18:912-925(2004).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-329; SER-1568 AND SER-1572,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   IDENTIFICATION IN THE BAF COMPLEX, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18765789; DOI=10.1101/gad.471408;
RA   Lange M., Kaynak B., Forster U.B., Toenjes M., Fischer J.J., Grimm C.,
RA   Schlesinger J., Just S., Dunkel I., Krueger T., Mebus S., Lehrach H.,
RA   Lurz R., Gobom J., Rottbauer W., Abdelilah-Seyfried S., Sperling S.;
RT   "Regulation of muscle development by DPF3, a novel histone acetylation and
RT   methylation reader of the BAF chromatin remodeling complex.";
RL   Genes Dev. 22:2370-2384(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175; SER-1512; SER-1516 AND
RP   SER-1528, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1568 AND SER-1572, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by enrichment
RT   and fractionation of phosphopeptides with strong anion exchange
RT   chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [12]
RP   PROBABLE INVOLVEMENT IN SCZD, VARIANT GLU-1546, AND CHARACTERIZATION OF
RP   VARIANT GLU-1546.
RX   PubMed=19363039; DOI=10.1093/hmg/ddp166;
RA   Koga M., Ishiguro H., Yazaki S., Horiuchi Y., Arai M., Niizato K.,
RA   Iritani S., Itokawa M., Inada T., Iwata N., Ozaki N., Ujike H., Kunugi H.,
RA   Sasaki T., Takahashi M., Watanabe Y., Someya T., Kakita A., Takahashi H.,
RA   Nawa H., Muchardt C., Yaniv M., Arinami T.;
RT   "Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in
RT   schizophrenia.";
RL   Hum. Mol. Genet. 18:2483-2494(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1512 AND SER-1516, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-997 AND LYS-999, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [15]
RP   INTERACTION WITH CEBPB.
RX   PubMed=20111005; DOI=10.1038/emboj.2010.3;
RA   Kowenz-Leutz E., Pless O., Dittmar G., Knoblich M., Leutz A.;
RT   "Crosstalk between C/EBPbeta phosphorylation, arginine methylation, and
RT   SWI/SNF/Mediator implies an indexing transcription factor code.";
RL   EMBO J. 29:1105-1115(2010).
RN   [16]
RP   INTERACTION WITH DEPF2.
RX   PubMed=20460684; DOI=10.1074/jbc.m109.087783;
RA   Tando T., Ishizaka A., Watanabe H., Ito T., Iida S., Haraguchi T.,
RA   Mizutani T., Izumi T., Isobe T., Akiyama T., Inoue J., Iba H.;
RT   "Requiem protein links RelB/p52 and the Brm-type SWI/SNF complex in a
RT   noncanonical NF-kappaB pathway.";
RL   J. Biol. Chem. 285:21951-21960(2010).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175; SER-329; SER-1568 AND
RP   SER-1572, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   INVOLVEMENT IN NCBRS.
RX   PubMed=22426308; DOI=10.1038/ng.2219;
RA   Tsurusaki Y., Okamoto N., Ohashi H., Kosho T., Imai Y., Hibi-Ko Y.,
RA   Kaname T., Naritomi K., Kawame H., Wakui K., Fukushima Y., Homma T.,
RA   Kato M., Hiraki Y., Yamagata T., Yano S., Mizuno S., Sakazume S., Ishii T.,
RA   Nagai T., Shiina M., Ogata K., Ohta T., Niikawa N., Miyatake S., Okada I.,
RA   Mizuguchi T., Doi H., Saitsu H., Miyake N., Matsumoto N.;
RT   "Mutations affecting components of the SWI/SNF complex cause Coffin-Siris
RT   syndrome.";
RL   Nat. Genet. 44:376-378(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-175; SER-329; SER-591;
RP   SER-666 AND SER-1377, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-172; SER-591; SER-1377 AND
RP   SER-1572, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=22952240; DOI=10.1074/jbc.r111.309302;
RA   Euskirchen G., Auerbach R.K., Snyder M.;
RT   "SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse
RT   functions.";
RL   J. Biol. Chem. 287:30897-30905(2012).
RN   [23]
RP   INTERACTION WITH ERCC6.
RX   PubMed=26030138; DOI=10.1371/journal.pone.0128558;
RA   Nicolai S., Filippi S., Caputo M., Cipak L., Gregan J., Ammerer G.,
RA   Frontini M., Willems D., Prantera G., Balajee A.S., Proietti-De-Santis L.;
RT   "Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group
RT   B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin
RT   Dynamics.";
RL   PLoS ONE 10:E0128558-E0128558(2015).
RN   [24]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=26601204; DOI=10.1126/sciadv.1500447;
RA   Kadoch C., Crabtree G.R.;
RT   "Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic
RT   insights gained from human genomics.";
RL   Sci. Adv. 1:E1500447-E1500447(2015).
RN   [25]
RP   VARIANTS NCBRS LYS-852; GLN-855 AND ILE-880.
RX   PubMed=23906836; DOI=10.1093/hmg/ddt366;
RA   Wieczorek D., Boegershausen N., Beleggia F., Steiner-Haldenstaett S.,
RA   Pohl E., Li Y., Milz E., Martin M., Thiele H., Altmueller J., Alanay Y.,
RA   Kayserili H., Klein-Hitpass L., Boehringer S., Wollstein A., Albrecht B.,
RA   Boduroglu K., Caliebe A., Chrzanowska K., Cogulu O., Cristofoli F.,
RA   Czeschik J.C., Devriendt K., Dotti M.T., Elcioglu N., Gener B.,
RA   Goecke T.O., Krajewska-Walasek M., Guillen-Navarro E., Hayek J., Houge G.,
RA   Kilic E., Simsek-Kiper P.O., Lopez-Gonzalez V., Kuechler A., Lyonnet S.,
RA   Mari F., Marozza A., Mathieu Dramard M., Mikat B., Morin G.,
RA   Morice-Picard F., Ozkinay F., Rauch A., Renieri A., Tinschert S.,
RA   Utine G.E., Vilain C., Vivarelli R., Zweier C., Nuernberg P., Rahmann S.,
RA   Vermeesch J., Luedecke H.J., Zeschnigk M., Wollnik B.;
RT   "A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser
RT   syndromes identifies a broad molecular and clinical spectrum converging on
RT   altered chromatin remodeling.";
RL   Hum. Mol. Genet. 22:5121-5135(2013).
RN   [26]
RP   STRUCTURE BY NMR OF 1377-1486.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the bromodomain of human SWI/SNF related matrix
RT   associated actin dependent regulator of chromatin subfamily A member 2.";
RL   Submitted (JAN-2007) to the PDB data bank.
RN   [27]
RP   VARIANTS NCBRS ALA-752; ARG-755; ILE-756; HIS-851; ASP-852; LYS-852;
RP   ARG-854; ASN-854; GLY-855; ARG-881; VAL-881; LEU-883; TYR-939; SER-946;
RP   PHE-946; CYS-1105; PRO-1105; PRO-1135; ARG-1146; VAL-1158; GLY-1159;
RP   LEU-1159; GLN-1159; HIS-1162; PRO-1188; VAL-1201; CYS-1202; GLY-1205 AND
RP   TRP-1213.
RX   PubMed=22366787; DOI=10.1038/ng.1105;
RA   Van Houdt J.K., Nowakowska B.A., Sousa S.B., van Schaik B.D., Seuntjens E.,
RA   Avonce N., Sifrim A., Abdul-Rahman O.A., van den Boogaard M.J., Bottani A.,
RA   Castori M., Cormier-Daire V., Deardorff M.A., Filges I., Fryer A.,
RA   Fryns J.P., Gana S., Garavelli L., Gillessen-Kaesbach G., Hall B.D.,
RA   Horn D., Huylebroeck D., Klapecki J., Krajewska-Walasek M., Kuechler A.,
RA   Lines M.A., Maas S., Macdermot K.D., McKee S., Magee A., de Man S.A.,
RA   Moreau Y., Morice-Picard F., Obersztyn E., Pilch J., Rosser E., Shannon N.,
RA   Stolte-Dijkstra I., Van Dijck P., Vilain C., Vogels A., Wakeling E.,
RA   Wieczorek D., Wilson L., Zuffardi O., van Kampen A.H., Devriendt K.,
RA   Hennekam R., Vermeesch J.R.;
RT   "Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser
RT   syndrome.";
RL   Nat. Genet. 44:445-449(2012).
RN   [28]
RP   VARIANT NCBRS GLU-1241.
RX   PubMed=27665729; DOI=10.1002/ajmg.a.37935;
RG   EuroEPINOMICS RES myoclonic astatic epilepsy working group;
RA   Tang S., Hughes E., Lascelles K., Simpson M.A., Pal D.K.;
RT   "New SMARCA2 mutation in a patient with Nicolaides-Baraitser syndrome and
RT   myoclonic astatic epilepsy.";
RL   Am. J. Med. Genet. A 173:195-199(2017).
CC   -!- FUNCTION: Involved in transcriptional activation and repression of
CC       select genes by chromatin remodeling (alteration of DNA-nucleosome
CC       topology). Component of SWI/SNF chromatin remodeling complexes that
CC       carry out key enzymatic activities, changing chromatin structure by
CC       altering DNA-histone contacts within a nucleosome in an ATP-dependent
CC       manner. Binds DNA non-specifically (PubMed:22952240, PubMed:26601204).
CC       Belongs to the neural progenitors-specific chromatin remodeling complex
CC       (npBAF complex) and the neuron-specific chromatin remodeling complex
CC       (nBAF complex). During neural development a switch from a
CC       stem/progenitor to a postmitotic chromatin remodeling mechanism occurs
CC       as neurons exit the cell cycle and become committed to their adult
CC       state. The transition from proliferating neural stem/progenitor cells
CC       to postmitotic neurons requires a switch in subunit composition of the
CC       npBAF and nBAF complexes. As neural progenitors exit mitosis and
CC       differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A
CC       and PHF10/BAF45A, are exchanged for homologous alternative
CC       ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-
CC       specific complexes (nBAF). The npBAF complex is essential for the self-
CC       renewal/proliferative capacity of the multipotent neural stem cells.
CC       The nBAF complex along with CREST plays a role regulating the activity
CC       of genes essential for dendrite growth (By similarity).
CC       {ECO:0000250|UniProtKB:Q6DIC0, ECO:0000303|PubMed:22952240,
CC       ECO:0000303|PubMed:26601204}.
CC   -!- SUBUNIT: Component of the multiprotein chromatin-remodeling complexes
CC       SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. The
CC       canonical complex contains a catalytic subunit (either
CC       SMARCA4/BRG1/BAF190A or SMARCA2/BRM/BAF190B) and at least SMARCE1,
CC       ACTL6A/BAF53, SMARCC1/BAF155, SMARCC2/BAF170, and SMARCB1/SNF5/BAF47.
CC       Other subunits specific to each of the complexes may also be present
CC       permitting several possible combinations developmentally and tissue
CC       specific (Probable). Component of the BAF complex, which includes at
CC       least actin (ACTB), ARID1A/BAF250A, ARID1B/BAF250B, SMARCA2/BRM,
CC       SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57,
CC       SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more
CC       SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C (PubMed:18765789). In
CC       muscle cells, the BAF complex also contains DPF3. Component of neural
CC       progenitors-specific chromatin remodeling complex (npBAF complex)
CC       composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A,
CC       SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A,
CC       SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170,
CC       PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific
CC       chromatin remodeling complex (nBAF complex) composed of at least,
CC       ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C,
CC       SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47,
CC       SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B,
CC       DPF3/BAF45C, ACTL6B/BAF53B and actin. Interacts with PHF10/BAF45A (By
CC       similarity). Interacts with CEBPB (when not
CC       methylated)(PubMed:20111005). Interacts with TOPBP1 (PubMed:15075294).
CC       Interacts with CEBPA (when phosphorylated) (PubMed:15107404). Interacts
CC       with DPF2 (PubMed:20460684). Interacts with ERCC6 (PubMed:26030138).
CC       {ECO:0000250|UniProtKB:Q6DIC0, ECO:0000269|PubMed:15075294,
CC       ECO:0000269|PubMed:15107404, ECO:0000269|PubMed:18765789,
CC       ECO:0000269|PubMed:20111005, ECO:0000269|PubMed:20460684,
CC       ECO:0000269|PubMed:26030138, ECO:0000303|PubMed:22952240,
CC       ECO:0000303|PubMed:26601204}.
CC   -!- INTERACTION:
CC       P51531; O14497: ARID1A; NbExp=3; IntAct=EBI-679562, EBI-637887;
CC       P51531; Q8NFD5: ARID1B; NbExp=3; IntAct=EBI-679562, EBI-679921;
CC       P51531; Q07666: KHDRBS1; NbExp=2; IntAct=EBI-679562, EBI-1364;
CC       P51531; P51608: MECP2; NbExp=4; IntAct=EBI-679562, EBI-1189067;
CC       P51531; Q9NRD5: PICK1; NbExp=2; IntAct=EBI-679562, EBI-79165;
CC       P51531; O00560: SDCBP; NbExp=2; IntAct=EBI-679562, EBI-727004;
CC       P51531; Q8TAQ2: SMARCC2; NbExp=2; IntAct=EBI-679562, EBI-357418;
CC       P51531; P04326: tat; Xeno; NbExp=8; IntAct=EBI-679562, EBI-7333987;
CC       P51531-2; Q8N7W2-2: BEND7; NbExp=3; IntAct=EBI-10212306, EBI-10181188;
CC       P51531-2; O00560: SDCBP; NbExp=3; IntAct=EBI-10212306, EBI-727004;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P51531-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P51531-2; Sequence=VSP_000577;
CC   -!- DISEASE: Nicolaides-Baraitser syndrome (NCBRS) [MIM:601358]: A rare
CC       disorder characterized by severe mental retardation with absent or
CC       limited speech, seizures, short stature, sparse hair, typical facial
CC       characteristics, brachydactyly, prominent finger joints and broad
CC       distal phalanges. Some of the features are progressive with time.
CC       {ECO:0000269|PubMed:22366787, ECO:0000269|PubMed:22426308,
CC       ECO:0000269|PubMed:23906836, ECO:0000269|PubMed:27665729}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Schizophrenia (SCZD) [MIM:181500]: A complex, multifactorial
CC       psychotic disorder or group of disorders characterized by disturbances
CC       in the form and content of thought (e.g. delusions, hallucinations), in
CC       mood (e.g. inappropriate affect), in sense of self and relationship to
CC       the external world (e.g. loss of ego boundaries, withdrawal), and in
CC       behavior (e.g bizarre or apparently purposeless behavior). Although it
CC       affects emotions, it is distinguished from mood disorders in which such
CC       disturbances are primary. Similarly, there may be mild impairment of
CC       cognitive function, and it is distinguished from the dementias in which
CC       disturbed cognitive function is considered primary. Some patients
CC       manifest schizophrenic as well as bipolar disorder symptoms and are
CC       often given the diagnosis of schizoaffective disorder.
CC       {ECO:0000269|PubMed:19363039}. Note=Disease susceptibility may be
CC       associated with variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the SNF2/RAD54 helicase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SWI/SNF related, matrix associated, actin dependent
CC       regulator of chromatin, subfamily a, member 2 (SMARCA2); Note=Leiden
CC       Open Variation Database (LOVD);
CC       URL="https://databases.lovd.nl/shared/genes/SMARCA2";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X72889; CAA51407.1; -; mRNA.
DR   EMBL; D26155; BAA05142.1; -; mRNA.
DR   EMBL; AL359076; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL138755; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58811.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58813.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58814.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58815.1; -; Genomic_DNA.
DR   CCDS; CCDS34977.1; -. [P51531-1]
DR   CCDS; CCDS34978.1; -. [P51531-2]
DR   PIR; S39580; S39580.
DR   PIR; S45251; S45251.
DR   RefSeq; NP_001276325.1; NM_001289396.1. [P51531-1]
DR   RefSeq; NP_001276326.1; NM_001289397.1.
DR   RefSeq; NP_003061.3; NM_003070.4. [P51531-1]
DR   RefSeq; NP_620614.2; NM_139045.3. [P51531-2]
DR   PDB; 2DAT; NMR; -; A=1377-1504.
DR   PDB; 4QY4; X-ray; 1.97 A; A/B/C=1373-1511.
DR   PDB; 5DKC; X-ray; 1.60 A; A=1373-1511.
DR   PDB; 5DKH; X-ray; 1.70 A; A/B/C=1373-1511.
DR   PDB; 6EG2; X-ray; 2.98 A; A=705-955.
DR   PDB; 6EG3; X-ray; 2.84 A; A=705-955.
DR   PDB; 6HAX; X-ray; 2.35 A; A/E=1373-1511.
DR   PDB; 6HAY; X-ray; 2.24 A; A/E=1373-1511.
DR   PDB; 6HAZ; X-ray; 1.31 A; A/B=1373-1511.
DR   PDBsum; 2DAT; -.
DR   PDBsum; 4QY4; -.
DR   PDBsum; 5DKC; -.
DR   PDBsum; 5DKH; -.
DR   PDBsum; 6EG2; -.
DR   PDBsum; 6EG3; -.
DR   PDBsum; 6HAX; -.
DR   PDBsum; 6HAY; -.
DR   PDBsum; 6HAZ; -.
DR   SMR; P51531; -.
DR   BioGRID; 112479; 204.
DR   ComplexPortal; CPX-1164; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1194; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1201; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1202; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1203; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1205; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1207; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1210; SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1213; Neural progenitor-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1217; Neuron-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1220; Brain-specific SWI/SNF ATP-dependent chromatin remodeling complex, ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1223; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6A-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-1225; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1A-SMARCA2 variant.
DR   ComplexPortal; CPX-1227; Muscle cell-specific SWI/SNF ATP-dependent chromatin remodeling complex, ACTL6B-ARID1B-SMARCA2 variant.
DR   ComplexPortal; CPX-4084; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRA-SMARCA2 variant.
DR   ComplexPortal; CPX-4203; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6A-BICRAL-SMARCA2 variant.
DR   ComplexPortal; CPX-4223; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRA-SMARCA2 variant.
DR   ComplexPortal; CPX-4224; GBAF (SWI/SNF) ATP-dependent chromatin remodeling complex, ACTL6B-BICRAL-SMARCA2 variant.
DR   CORUM; P51531; -.
DR   DIP; DIP-29005N; -.
DR   IntAct; P51531; 89.
DR   MINT; P51531; -.
DR   STRING; 9606.ENSP00000265773; -.
DR   BindingDB; P51531; -.
DR   ChEMBL; CHEMBL2362979; -.
DR   GlyGen; P51531; 1 site.
DR   iPTMnet; P51531; -.
DR   MetOSite; P51531; -.
DR   PhosphoSitePlus; P51531; -.
DR   BioMuta; SMARCA2; -.
DR   DMDM; 212276472; -.
DR   EPD; P51531; -.
DR   jPOST; P51531; -.
DR   MassIVE; P51531; -.
DR   MaxQB; P51531; -.
DR   PaxDb; P51531; -.
DR   PeptideAtlas; P51531; -.
DR   PRIDE; P51531; -.
DR   ProteomicsDB; 56325; -. [P51531-1]
DR   ProteomicsDB; 56326; -. [P51531-2]
DR   ABCD; P51531; 1 sequenced antibody.
DR   Antibodypedia; 9105; 212 antibodies.
DR   DNASU; 6595; -.
DR   Ensembl; ENST00000349721; ENSP00000265773; ENSG00000080503. [P51531-1]
DR   Ensembl; ENST00000357248; ENSP00000349788; ENSG00000080503. [P51531-2]
DR   Ensembl; ENST00000382194; ENSP00000371629; ENSG00000080503. [P51531-2]
DR   Ensembl; ENST00000382203; ENSP00000371638; ENSG00000080503. [P51531-1]
DR   GeneID; 6595; -.
DR   KEGG; hsa:6595; -.
DR   UCSC; uc003zhc.5; human. [P51531-1]
DR   CTD; 6595; -.
DR   DisGeNET; 6595; -.
DR   GeneCards; SMARCA2; -.
DR   GeneReviews; SMARCA2; -.
DR   HGNC; HGNC:11098; SMARCA2.
DR   HPA; ENSG00000080503; Low tissue specificity.
DR   MalaCards; SMARCA2; -.
DR   MIM; 181500; phenotype.
DR   MIM; 600014; gene.
DR   MIM; 601358; phenotype.
DR   neXtProt; NX_P51531; -.
DR   OpenTargets; ENSG00000080503; -.
DR   Orphanet; 3051; Intellectual disability-sparse hair-brachydactyly syndrome.
DR   PharmGKB; PA35948; -.
DR   VEuPathDB; HostDB:ENSG00000080503.20; -.
DR   eggNOG; KOG0386; Eukaryota.
DR   GeneTree; ENSGT00940000154821; -.
DR   HOGENOM; CLU_000315_15_0_1; -.
DR   InParanoid; P51531; -.
DR   OMA; SHHFNIE; -.
DR   PhylomeDB; P51531; -.
DR   TreeFam; TF300785; -.
DR   PathwayCommons; P51531; -.
DR   Reactome; R-HSA-3214858; RMTs methylate histone arginines.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   SIGNOR; P51531; -.
DR   BioGRID-ORCS; 6595; 34 hits in 995 CRISPR screens.
DR   ChiTaRS; SMARCA2; human.
DR   EvolutionaryTrace; P51531; -.
DR   GeneWiki; SMARCA2; -.
DR   GenomeRNAi; 6595; -.
DR   Pharos; P51531; Tchem.
DR   PRO; PR:P51531; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; P51531; protein.
DR   Bgee; ENSG00000080503; Expressed in testis and 247 other tissues.
DR   ExpressionAtlas; P51531; baseline and differential.
DR   Genevisible; P51531; HS.
DR   GO; GO:0000785; C:chromatin; IDA:BHF-UCL.
DR   GO; GO:0045111; C:intermediate filament cytoskeleton; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0071565; C:nBAF complex; ISS:UniProtKB.
DR   GO; GO:0071564; C:npBAF complex; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016514; C:SWI/SNF complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IBA:GO_Central.
DR   GO; GO:0008094; F:DNA-dependent ATPase activity; IBA:GO_Central.
DR   GO; GO:0004386; F:helicase activity; TAS:ProtInc.
DR   GO; GO:0042393; F:histone binding; IEA:InterPro.
DR   GO; GO:0070615; F:nucleosome-dependent ATPase activity; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0043044; P:ATP-dependent chromatin remodeling; IBA:GO_Central.
DR   GO; GO:0006338; P:chromatin remodeling; TAS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; TAS:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0007286; P:spermatid development; IEA:Ensembl.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 2.20.28.130; -; 1.
DR   Gene3D; 3.40.50.10810; -; 1.
DR   InterPro; IPR006576; BRK_domain.
DR   InterPro; IPR037259; BRK_sf.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR014978; Gln-Leu-Gln_QLQ.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C.
DR   InterPro; IPR014012; HSA_dom.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR030088; SMARCA2.
DR   InterPro; IPR029295; SnAC.
DR   InterPro; IPR038718; SNF2-like_sf.
DR   InterPro; IPR000330; SNF2_dom.
DR   PANTHER; PTHR10799:SF541; PTHR10799:SF541; 1.
DR   Pfam; PF07533; BRK; 1.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   Pfam; PF07529; HSA; 1.
DR   Pfam; PF08880; QLQ; 1.
DR   Pfam; PF14619; SnAC; 1.
DR   Pfam; PF00176; SNF2_N; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00592; BRK; 1.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SMART; SM00573; HSA; 1.
DR   SMART; SM00951; QLQ; 1.
DR   SMART; SM01314; SnAC; 1.
DR   SUPFAM; SSF160481; SSF160481; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51204; HSA; 1.
DR   PROSITE; PS51666; QLQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; ATP-binding;
KW   Bromodomain; Disease variant; DNA-binding; Helicase; Hydrolase;
KW   Hypotrichosis; Isopeptide bond; Mental retardation; Neurogenesis;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Schizophrenia; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1590
FT                   /note="Probable global transcription activator SNF2L2"
FT                   /id="PRO_0000074352"
FT   DOMAIN          173..208
FT                   /note="QLQ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01001"
FT   DOMAIN          436..508
FT                   /note="HSA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00549"
FT   DOMAIN          736..901
FT                   /note="Helicase ATP-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   DOMAIN          1054..1216
FT                   /note="Helicase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00542"
FT   DOMAIN          1419..1489
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   NP_BIND         749..756
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00541"
FT   MOTIF           851..854
FT                   /note="DEGH box"
FT   COMPBIAS        216..238
FT                   /note="Poly-Gln"
FT   COMPBIAS        245..253
FT                   /note="Poly-Gln"
FT   COMPBIAS        559..562
FT                   /note="Poly-Arg"
FT   COMPBIAS        643..650
FT                   /note="Poly-Glu"
FT   COMPBIAS        1297..1301
FT                   /note="Poly-Glu"
FT   COMPBIAS        1518..1529
FT                   /note="Poly-Glu"
FT   MOD_RES         172
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         190
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P51532"
FT   MOD_RES         316
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6DIC0"
FT   MOD_RES         329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         588
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P51532"
FT   MOD_RES         591
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         604
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6DIC0"
FT   MOD_RES         666
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         670
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P51532"
FT   MOD_RES         997
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         999
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         1377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1512
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         1516
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         1528
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1568
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231"
FT   MOD_RES         1572
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18318008, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:24275569"
FT   CROSSLNK        1302
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:P51532"
FT   VAR_SEQ         1400..1417
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:8208605"
FT                   /id="VSP_000577"
FT   VARIANT         752
FT                   /note="G -> A (in NCBRS; dbSNP:rs281875198)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068180"
FT   VARIANT         755
FT                   /note="K -> R (in NCBRS; dbSNP:rs281875203)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068181"
FT   VARIANT         756
FT                   /note="T -> I (in NCBRS; dbSNP:rs281875191)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068182"
FT   VARIANT         851
FT                   /note="D -> H (in NCBRS; dbSNP:rs281875206)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068183"
FT   VARIANT         852
FT                   /note="E -> D (in NCBRS; dbSNP:rs281875193)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068184"
FT   VARIANT         852
FT                   /note="E -> K (in NCBRS; dbSNP:rs281875199)"
FT                   /evidence="ECO:0000269|PubMed:22366787,
FT                   ECO:0000269|PubMed:23906836"
FT                   /id="VAR_068185"
FT   VARIANT         854
FT                   /note="H -> N (in NCBRS)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068186"
FT   VARIANT         854
FT                   /note="H -> R (in NCBRS; dbSNP:rs281875202)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068187"
FT   VARIANT         855
FT                   /note="R -> G (in NCBRS; dbSNP:rs281875207)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068188"
FT   VARIANT         855
FT                   /note="R -> Q (in NCBRS; dbSNP:rs1471482709)"
FT                   /evidence="ECO:0000269|PubMed:23906836"
FT                   /id="VAR_076936"
FT   VARIANT         880
FT                   /note="T -> I (in NCBRS)"
FT                   /evidence="ECO:0000269|PubMed:23906836"
FT                   /id="VAR_076937"
FT   VARIANT         881
FT                   /note="G -> R (in NCBRS; dbSNP:rs281875194)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068189"
FT   VARIANT         881
FT                   /note="G -> V (in NCBRS; dbSNP:rs281875185)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068190"
FT   VARIANT         883
FT                   /note="P -> L (in NCBRS; dbSNP:rs281875188)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068191"
FT   VARIANT         939
FT                   /note="H -> Y (in NCBRS; dbSNP:rs281875190)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068192"
FT   VARIANT         946
FT                   /note="L -> F (in NCBRS; dbSNP:rs281875205)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068193"
FT   VARIANT         946
FT                   /note="L -> S (in NCBRS; dbSNP:rs281875200)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068194"
FT   VARIANT         1105
FT                   /note="R -> C (in NCBRS; dbSNP:rs281875192)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068195"
FT   VARIANT         1105
FT                   /note="R -> P (in NCBRS; dbSNP:rs281875197)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068196"
FT   VARIANT         1135
FT                   /note="L -> P (in NCBRS; dbSNP:rs281875195)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068197"
FT   VARIANT         1146
FT                   /note="S -> R (in NCBRS; dbSNP:rs281875204)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068198"
FT   VARIANT         1158
FT                   /note="D -> V (in NCBRS; dbSNP:rs281875240)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068199"
FT   VARIANT         1159
FT                   /note="R -> G (in NCBRS; dbSNP:rs281875184)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068200"
FT   VARIANT         1159
FT                   /note="R -> L (in NCBRS; dbSNP:rs281875187)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068201"
FT   VARIANT         1159
FT                   /note="R -> Q (in NCBRS; dbSNP:rs281875187)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068202"
FT   VARIANT         1162
FT                   /note="R -> H (in NCBRS; dbSNP:rs281875186)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068203"
FT   VARIANT         1188
FT                   /note="A -> P (in NCBRS; dbSNP:rs281875196)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068204"
FT   VARIANT         1201
FT                   /note="A -> V (in NCBRS; dbSNP:rs281875189)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068205"
FT   VARIANT         1202
FT                   /note="G -> C (in NCBRS; dbSNP:rs281875239)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068206"
FT   VARIANT         1205
FT                   /note="D -> G (in NCBRS; dbSNP:rs281875201)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068207"
FT   VARIANT         1213
FT                   /note="R -> W (in NCBRS; dbSNP:rs281875238)"
FT                   /evidence="ECO:0000269|PubMed:22366787"
FT                   /id="VAR_068208"
FT   VARIANT         1241
FT                   /note="Q -> E (in NCBRS)"
FT                   /evidence="ECO:0000269|PubMed:27665729"
FT                   /id="VAR_078815"
FT   VARIANT         1416
FT                   /note="G -> A (in dbSNP:rs3793510)"
FT                   /id="VAR_049501"
FT   VARIANT         1546
FT                   /note="D -> E (associated with schizophrenia in some
FT                   populations; results in reduced localization to the
FT                   nucleus; decreased interaction with chromatin;
FT                   dbSNP:rs2296212)"
FT                   /evidence="ECO:0000269|PubMed:19363039"
FT                   /id="VAR_049502"
FT   CONFLICT        237..240
FT                   /note="Missing (in Ref. 1; CAA51407)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        394
FT                   /note="Q -> E (in Ref. 2; BAA05142)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        513
FT                   /note="G -> S (in Ref. 2; BAA05142)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        711
FT                   /note="R -> W (in Ref. 1; CAA51407)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1139
FT                   /note="D -> H (in Ref. 2; BAA05142)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1394
FT                   /note="V -> C (in Ref. 1; CAA51407)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1400
FT                   /note="R -> S (in Ref. 1; CAA51407)"
FT                   /evidence="ECO:0000305"
FT   HELIX           726..740
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          745..747
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          751..753
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           755..768
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          776..779
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           782..795
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          797..799
FT                   /evidence="ECO:0007744|PDB:6EG2"
FT   STRAND          801..804
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           808..812
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           815..820
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          824..828
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           830..835
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           837..840
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          846..855
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           859..870
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   STRAND          874..882
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           888..898
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   TURN            900..903
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           909..914
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           915..917
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           928..942
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           943..945
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           951..953
FT                   /evidence="ECO:0007744|PDB:6EG3"
FT   HELIX           1381..1396
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   STRAND          1418..1420
FT                   /evidence="ECO:0007744|PDB:2DAT"
FT   HELIX           1425..1427
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   TURN            1433..1435
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   HELIX           1437..1442
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   HELIX           1449..1457
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   HELIX           1464..1481
FT                   /evidence="ECO:0007744|PDB:6HAZ"
FT   HELIX           1487..1507
FT                   /evidence="ECO:0007744|PDB:6HAZ"
SQ   SEQUENCE   1590 AA;  181279 MW;  CE69BBB287D35AB5 CRC64;
     MSTPTDPGAM PHPGPSPGPG PSPGPILGPS PGPGPSPGSV HSMMGPSPGP PSVSHPMPTM
     GSTDFPQEGM HQMHKPIDGI HDKGIVEDIH CGSMKGTGMR PPHPGMGPPQ SPMDQHSQGY
     MSPHPSPLGA PEHVSSPMSG GGPTPPQMPP SQPGALIPGD PQAMSQPNRG PSPFSPVQLH
     QLRAQILAYK MLARGQPLPE TLQLAVQGKR TLPGLQQQQQ QQQQQQQQQQ QQQQQQQQPQ
     QQPPQPQTQQ QQQPALVNYN RPSGPGPELS GPSTPQKLPV PAPGGRPSPA PPAAAQPPAA
     AVPGPSVPQP APGQPSPVLQ LQQKQSRISP IQKPQGLDPV EILQEREYRL QARIAHRIQE
     LENLPGSLPP DLRTKATVEL KALRLLNFQR QLRQEVVACM RRDTTLETAL NSKAYKRSKR
     QTLREARMTE KLEKQQKIEQ ERKRRQKHQE YLNSILQHAK DFKEYHRSVA GKIQKLSKAV
     ATWHANTERE QKKETERIEK ERMRRLMAED EEGYRKLIDQ KKDRRLAYLL QQTDEYVANL
     TNLVWEHKQA QAAKEKKKRR RRKKKAEENA EGGESALGPD GEPIDESSQM SDLPVKVTHT
     ETGKVLFGPE APKASQLDAW LEMNPGYEVA PRSDSEESDS DYEEEDEEEE SSRQETEEKI
     LLDPNSEEVS EKDAKQIIET AKQDVDDEYS MQYSARGSQS YYTVAHAISE RVEKQSALLI
     NGTLKHYQLQ GLEWMVSLYN NNLNGILADE MGLGKTIQTI ALITYLMEHK RLNGPYLIIV
     PLSTLSNWTY EFDKWAPSVV KISYKGTPAM RRSLVPQLRS GKFNVLLTTY EYIIKDKHIL
     AKIRWKYMIV DEGHRMKNHH CKLTQVLNTH YVAPRRILLT GTPLQNKLPE LWALLNFLLP
     TIFKSCSTFE QWFNAPFAMT GERVDLNEEE TILIIRRLHK VLRPFLLRRL KKEVESQLPE
     KVEYVIKCDM SALQKILYRH MQAKGILLTD GSEKDKKGKG GAKTLMNTIM QLRKICNHPY
     MFQHIEESFA EHLGYSNGVI NGAELYRASG KFELLDRILP KLRATNHRVL LFCQMTSLMT
     IMEDYFAFRN FLYLRLDGTT KSEDRAALLK KFNEPGSQYF IFLLSTRAGG LGLNLQAADT
     VVIFDSDWNP HQDLQAQDRA HRIGQQNEVR VLRLCTVNSV EEKILAAAKY KLNVDQKVIQ
     AGMFDQKSSS HERRAFLQAI LEHEEENEEE DEVPDDETLN QMIARREEEF DLFMRMDMDR
     RREDARNPKR KPRLMEEDEL PSWIIKDDAE VERLTCEEEE EKIFGRGSRQ RRDVDYSDAL
     TEKQWLRAIE DGNLEEMEEE VRLKKRKRRR NVDKDPAKED VEKAKKRRGR PPAEKLSPNP
     PKLTKQMNAI IDTVINYKDR CNVEKVPSNS QLEIEGNSSG RQLSEVFIQL PSRKELPEYY
     ELIRKPVDFK KIKERIRNHK YRSLGDLEKD VMLLCHNAQT FNLEGSQIYE DSIVLQSVFK
     SARQKIAKEE ESEDESNEEE EEEDEEESES EAKSVKVKIK LNKKDDKGRD KGKGKKRPNR
     GKAKPVVSDF DSDEEQDERE QSEGSGTDDE
//
